Biofrontera (BFRI) to Release Earnings on Friday

Biofrontera (NASDAQ:BFRI) is expected to post its Q4 2025 results after the market closes on Friday, April 3rd. Analysts expect Biofrontera to post earnings of $0.1950 per share and revenue of $16.1460 million for the quarter. Investors may review the information on the company’s upcoming Q4 2025 earning report for the latest details on the call scheduled for Thursday, March 19, 2026 at 10:00 AM ET.

Biofrontera (NASDAQ:BFRI) last posted its quarterly earnings data on Thursday, March 19th. The company reported $0.50 earnings per share for the quarter, beating the consensus estimate of $0.29 by $0.21. Biofrontera had a negative net margin of 25.26% and a negative return on equity of 1,236.11%. The company had revenue of $17.10 million during the quarter, compared to analyst estimates of $16.15 million. On average, analysts expect Biofrontera to post $-3 EPS for the current fiscal year and $-1 EPS for the next fiscal year.

Biofrontera Stock Up 3.9%

NASDAQ BFRI opened at $0.81 on Wednesday. Biofrontera has a 12 month low of $0.54 and a 12 month high of $1.19. The company’s 50 day simple moving average is $0.87 and its 200 day simple moving average is $0.88. The company has a market capitalization of $9.42 million, a P/E ratio of -0.79 and a beta of 0.61. The company has a debt-to-equity ratio of 0.44, a current ratio of 1.52 and a quick ratio of 1.40.

Hedge Funds Weigh In On Biofrontera

An institutional investor recently raised its position in Biofrontera stock. Geode Capital Management LLC grew its holdings in Biofrontera Inc. (NASDAQ:BFRI) by 54.2% during the fourth quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 65,677 shares of the company’s stock after purchasing an additional 23,074 shares during the period. Geode Capital Management LLC owned about 0.56% of Biofrontera worth $37,000 as of its most recent SEC filing. 10.08% of the stock is owned by institutional investors.

Biofrontera Company Profile

Biofrontera AG is a specialty biopharmaceutical company focused on the research, development and commercialization of products for dermatological applications. The company’s core expertise lies in photodynamic therapy (PDT), a treatment modality that uses a photosensitizing agent activated by a specific light source to target diseased skin cells while sparing surrounding healthy tissue.

The flagship product in Biofrontera’s portfolio is Ameluz (aminolevulinic acid hydrochloride 10 % gel), which has received marketing approval in the European Union for treatment of actinic keratosis and basal cell carcinoma, and in the United States for actinic keratosis.